Recent News

• 11.05.2026 - Organogenesis Holdings Inc. Reports Third Quarter 2026 Financial Results
• 10.12.2026 - Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot Ulcers
• 10.12.2026 - Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026
• 08.06.2026 - Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results
• 08.06.2026 - Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results
• 07.27.2026 - Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers
• 07.09.2026 - Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026
• 07.06.2026 - Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis
• 05.07.2026 - Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results
• 04.28.2026 - Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®

Recent Filings

• 11.05.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.05.2026 - 8-K Current report
• 11.05.2026 - EX-99.1 EX-99.1
• 08.06.2026 - 8-K Current report
• 08.06.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 08.06.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.06.2026 - 8-K Current report
• 08.06.2026 - EX-99.1 EX-99.1
• 06.16.2026 - 8-K Current report
• 05.07.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]